Trump Administration Negotiates Reduced Prices for Obesity Drugs

The Trump administration is currently in negotiations with pharmaceutical companies Novo Nordisk and Eli Lilly to potentially lower prices for their popular weight loss medications, including the injectable drug Wegovy. Under the proposed agreements, a month’s supply of these drugs could cost approximately $149 and may be covered for eligible Medicare beneficiaries.

These ongoing discussions, first reported by Endpoint News, aim to enhance patient access to effective obesity treatments. Sources familiar with the negotiations indicated that an announcement could be made as soon as this week, contingent upon the success of the talks. A spokesperson for the White House did not provide immediate comments on the situation.

During a briefing, White House Press Secretary Karoline Leavitt expressed the administration’s commitment to reducing drug prices without revealing further details. She highlighted President Trump’s dedication to the issue, referencing an executive order signed in May that mandates companies charge U.S. patients the same prices as those in other countries. This pricing strategy is known as “Most Favored Nation” pricing.

In a statement, a representative from Novo Nordisk confirmed that the company is engaged in constructive discussions regarding the executive order. They emphasized their focus on improving patient access and affordability, stating, “We will continue to work to find solutions that help people access the medication they need.”

Eli Lilly also acknowledged its ongoing negotiations, with a spokesperson stating, “Lilly is in discussions with the administration to further expand patient access, preserve innovation, and promote affordability of our medicines.” However, specific details of the talks remain undisclosed.

As the discussions progress, the potential for reduced prices on weight loss medications could significantly impact many individuals seeking affordable treatment options. The outcome of these negotiations may set a precedent for future pricing strategies in the pharmaceutical industry, particularly concerning high-demand medications.